Motus GI Announces Issuance of European Patent for the Pure-Vu® System

“This European patent strengthens our intellectual property and confirms the Pure-Vu System’s place as an important proprietary technology in the European market,” said Mark Pomeranz, CEO of Motus. “Combined with our recent European regulatory approval, this patent will enable us to establish a strong presence in Europe, where 6 million colonoscopies are performed annually.”

The Pure-Vu System is currently being introduced on a pilot basis in the U.S. market. Motus is planning to initiate a full commercial launch in the U.S. and select international markets in 2019. The Company recently announced CE mark approval for the Pure-Vu System in Europe and expects to continue to involve key European clinical centers in the post-approval clinical trials that it plans to conduct during the next 12 months and beyond.

“With 30 million colonoscopy procedures performed annually worldwide, there is tremendous potential for the Pure-Vu System to improve clinical outcomes and reduce costs. Specifically, of the nearly 4 million in-patient colonoscopy procedures performed every year, where nearly 50% of patients present with an inadequately prepped colon. This contributes to long procedure times, repeat procedures, poor detection rates and extended hospital stays, all of which we believe the Pure-Vu System can help address by effectively and efficiently cleansing the colon during the procedure,” Mr. Pomeranz added.

About the Pure-Vu® System

The Pure-Vu® System is a 510(k) U.S. Food and Drug Administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. The Pure-Vu System has received CE mark approval in Europe.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company’s filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended from time to time, under the caption “Risk Factors.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005280/en/